Answers are grounded in this paper and cite their sources.
Mature (non-anaplastic) peripheral T-cell lymphomas (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas (NHLs), with exceedingly rare occurrence in children and adolescents, comprising <2% of childhood NHLs. In contrast to adult patients with recent advances in understanding the oncogenic mechanisms of many entities, little is known about the clinical presentation, etiology, pathophysiology and genetic features of pediatric PTCLs. The available outcome data on pediatric patients with non-anaplastic PTCLs show lower survival rates compared to other NHL-entities. No standard treatment strategy is established for pediatric patients with PTCL due to the rarity and heterogeneity of the lymphomas with very small groups of patients, precluding randomized prospective trials. Often, therapy is derived from adult studies, although available clinical and genetic studies show clear differences between PTCLs occurring in adult and pediatric patients. In view of guarded outcome with conventional therapies, novel therapeutic approaches incorporating targeted therapy of specific cellular pathways involved in lymphomagenesis or immunotherapies are needed to improve the clinical outcomes of PTCL patients. In this review we will summarize the current knowledge about pathogenesis, clinical presentation, diagnostic approach and possible therapy of the most common subtypes of PTCL in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Moser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: